Company Summary - ReNeuron Group PLC (LSE:RENE)
7.00p
0.08p
(-1.14%)
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £23.774m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications
| Financials - Annual Report (31/03/2009) | ||
|---|---|---|
| Turnover | £m | 0.09 |
| Pre-tax Profit | £m | -4.67 |
| EPS | p | -1.96 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Prof. Trevor Jones | Chairman |
| Michael Hunt | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
ReNeuron Holdings Ltd; ReNeuron Ltd
Broker Sentiment (2 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Positive data presented at leading U... | 16/11/2009 |
| ReNeuron to present at Royal Socie... | 22/10/2009 |
| Publication of new research using R... | 02/10/2009 |